Table 2. Treatment patterns during follow-up period.

	All patients (N=1,298)
Length of follow-up (days), mean [median]	229 [140]
Systemic therapy during the follow-up period, N (%)
Number of lines of therapy identified on or after the index date, mean ± SD [median]	0.9±1.1 [1.0]
0 lines of therapy identified on or after index date, N (%)	514 (39.6)
1 line of therapy identified on or after index date, N (%)	510 (39.3)
≥2 lines of therapy identified on or after index date, N (%)	274 (21.1)
Second-line systemic therapy†
Patients receiving second-line therapy, N (%)	784 (60.4)
Second-line systemic therapy† including, N (%)
Gemcitabine	241 (30.7)
Fluorouracil	316 (40.3)
Capecitabine	230 (29.3)
Other systemic therapy‡	52 (6.6)
Duration of second-line systemic therapy† (days), mean ± SD [median]	87.9±104.4 [56.0]
Time from index date to second-line therapy among patients with second-line initiation after index date§ (days), mean ± SD [median]	92.6±142.6 [35.0]
Third-line systemic therapy¶, N (%)
Patients receiving ≥2 lines of therapy on or after the index date	274 (21.1)
Third-line systemic therapy¶ including, N (%)
Gemcitabine	103 (37.6)
Fluorouracil	104 (38.0)
Capecitabine	47 (17.2)
Other systemic therapy§	36 (13.1)
Duration of third-line systemic therapy¶ (days), mean ± SD [median]	80.7±100.7 [49.0]

^†, second-line systemic therapy is defined in this study as the next-line of treatment after failure of the first-line systemic therapy containing either gemcitabine or fluorouracil. Categories are not mutually exclusive; ^‡, other systemic therapy regimens including irinotecan, nab-paclitaxel, and/or oxaliplatin; ^§, 274 patients initiated a second-line therapy after the index date; 510 patients had index date defined as initiation of second-line therapy. ^¶, third-line systemic therapy is defined in this study as the next-line treatment after second-line therapy defined above. Categories are not mutually exclusive. SD, standard deviation.